Abstract
Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Oldenburg J, Brackmann HH, Schwaab R. Risk factors for inhibitor development in hemophilia A. Haematologica. 2000;85(10 Suppl):7–13; discussion − 4.
Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A, et al. Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost. 1995;74(6):1402–6.
Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M, et al. F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood. 2012;119(12):2922–34.
Astermark J, Berntorp E, White GC, Kroner BL, Group MS. The Malmö International Brother Study (MIBS): further support for genetic predisposition to inhibitor development in hemophilia patients. Haemophilia. 2001;7(3):267–72.
Gouw SC, van den Berg HM, Fischer K, Auerswald G, Carcao M, Chalmers E, et al. Intensity of factor VIII treatment and inhibitor development in children with severe hemophilia A: the RODIN study. Blood. 2013;121(20):4046–55.
Gouw SC, van der Bom JG, Auerswald G, Ettinghausen CE, Tedgård U, van den Berg HM. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood. 2007;109(11):4693–7.
Gouw SC, van der Bom JG, Ljung R, Escuriola C, Cid AR, Claeyssens-Donadel S, et al. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med. 2013;368(3):231–9.
Peyvandi F, Mannucci PM, Garagiola I, El-Beshlawy A, Elalfy M, Ramanan V, et al. A randomized trial of factor VIII and neutralizing antibodies in Hemophilia A. N Engl J Med. 2016;374(21):2054–64.
Meeks SL, Healey JF, Parker ET, Barrow RT, Lollar P. Nonclassical anti-C2 domain antibodies are present in patients with factor VIII inhibitors. Blood. 2008;112(4):1151–3.
Markovitz RC, Healey JF, Parker ET, Meeks SL, Lollar P. The diversity of the immune response to the A2 domain of human factor VIII. Blood. 2013;121(14):2785–95.
Miller CH. Laboratory testing for factor VIII and IX inhibitors in haemophilia: a review. Haemophilia. 2018;24(2):186–97.
Eckhardt CL, van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G, et al. Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood. 2013;122(11):1954–62.
Hay CR, DiMichele DM, Study IIT. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood. 2012;119(6):1335–44.
Eubanks J, Baldwin WH, Markovitz R, Parker ET, Cox C, Kempton CL, et al. A subset of high-titer anti-factor VIII A2 domain antibodies is responsive to treatment with factor VIII. Blood. 2016;127(16):2028–34.
Nakar C, Manco-Johnson MJ, Lail A, Donfield S, Maahs J, Chong Y, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia. 2015;21(3):365–73.
Konkle BA, Ebbesen LS, Erhardtsen E, Bianco RP, Lissitchkov T, Rusen L, et al. Randomized, prospective clinical trial of recombinant factor VIIa for secondary prophylaxis in hemophilia patients with inhibitors. J Thromb Haemost. 2007;5(9):1904–13.
Leissinger C, Gringeri A, Antmen B, Berntop E, Biasoli C, Carpenter S, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med. 2011;365(18):1684–92.
Oldenburg J, Mahlangu JN, Kim B, Schmitt C, Callaghan MU, Young G, et al. Emicizumab prophylaxis in Hemophilia A with inhibitors. N Engl J Med. 2017;377(9):809–18.
Chowdary P, Lethagen S, Friedrich U, Brand B, Hay C, Abdul Karim F, et al. Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost. 2015;13(5):743–54.
Pasi KJ, Rangarajan S, Georgiev P, Mant T, Creagh MD, Lissitchkov T, et al. Targeting of antithrombin in Hemophilia A or B with RNAi therapy. N Engl J Med. 2017;377(9):819–28.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2020 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Saini, S., Dunn, A.L. (2020). Clinical Care of a Child with Hemophilia A and Inhibitors. In: Dunn, A., Kerlin, B., O'Brien, S., Rose, M., Kumar, R. (eds) Pediatric Bleeding Disorders. Springer, Cham. https://doi.org/10.1007/978-3-030-31661-7_2
Download citation
DOI: https://doi.org/10.1007/978-3-030-31661-7_2
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-31660-0
Online ISBN: 978-3-030-31661-7
eBook Packages: MedicineMedicine (R0)